R&D channel feed

Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Last year
Startups
Coronavirus

As Ver­tex’s piv­otal pain read­out looms, non-opi­oid drug de­vel­op­ment faces a reck­on­ing

Last year
In Focus

Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Last year

Am­gen touts two can­cer study wins with DLL3, Lumakras amid sec­ond-quar­ter earn­ings up­date

Last year

J&J sets its sights on par­ents — and chil­dren’s vi­sion — in new back-to-school so­cial me­dia cam­paign

Last year

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Last year
Deals

Hous­ton biotech Ar­a­vive re­ports PhI­II ovar­i­an can­cer fail, shares nose­dive

Last year

Sarep­ta dos­es first pa­tient with Duchenne gene ther­a­py fol­low­ing ac­cel­er­at­ed ap­proval

Last year
Cell/Gene Tx

A broad new idea for treat­ing vi­ral in­fec­tions: blow­ing up their pro­tec­tive mem­branes

Last year
Discovery

Ver­tex dos­es first pa­tient with next type 1 di­a­betes cell ther­a­py pro­gram, while padding its cof­fers with strong Q2

Last year

Failed tri­als for 16 IGF-1R in­hibitors and $1.6B lat­er: Time for bet­ter pre­clin­i­cal mod­els?

Last year

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Last year

FDA asks Citius for en­hanced prod­uct test­ing in CRL for non-Hodgkin lym­phoma drug Lym­phir

Last year

Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Last year

Mer­ck touts topline PhI­II Keytru­da da­ta in pre-surgery breast can­cer treat­ment

Last year
Pharma

Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Last year
Pharma

Ho­mol­o­gy shut­ters de­vel­op­ment as ge­net­ic med­i­cines biotech flash­es ‘for sale’ sign, lays off 80 em­ploy­ees

Last year
People
Cell/Gene Tx

Take­da re­veals PhII fail for rare ge­net­ic con­di­tion, looks to new prod­uct pipeline to bol­ster growth

Last year
Pharma

Ako­rn’s bank­rupt­cy, re­calls bring a drug to treat lead poi­son­ing in­to short­age

Last year
Manufacturing

In two late-stage tri­als of Lil­ly’s tirzepatide, par­tic­i­pants lost one-quar­ter of their weight

Last year

'An un­holy union': Stan­ford sci­en­tists cre­ate a drug that flips can­cer dri­ver in­to killer

Last year

Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Last year
People

Af­ter years of de­lay, Roche takes one of Spark’s he­mo­phil­ia gene ther­a­pies in­to PhI­II, drops an­oth­er

Last year
Cell/Gene Tx

‘This is not a sci­ence prob­lem any­more': Paths emerge for scal­ing up rare dis­ease med­i­cine

Last year
In Focus
First page Previous page 74757677787980 Next page Last page
A service from the Financial Times